Just under a quarter of the patients in both groups received also new drugs for heart failure: ARNI (angiotensin receptor neprilysin inhibitor) and sodium-glucose cotransporter-2 (SGLT2) inhibitors. The gene discussed is SLC5A2; the disease is heart failure.